For decades, the prescription has barely changed: 150 minutes of moderate exercise a week, preferably in sessions that last. The WHO, the CDC, and the American Heart Association agree, and most adults fail the test anyway. In the United States, roughly three in four do not meet the aerobic guideline, and the standard response has been to urge harder, as though the only problem were motivation.
Emmanuel Stamatakis, a physical-activity epidemiologist at the University of Sydney, suspected the model itself was broken. Structured exercise occupies a sliver of the week, but the remaining hundreds of waking hours contain something exercise science had never measured well: brief, vigorous bursts embedded in ordinary life: sprinting up the stairs because you are late, hauling grocery bags at speed, chasing a toddler across a park. His team named the phenomenon vigorous intermittent lifestyle physical activity, VILPA for short, and asked whether these accidental workouts count.
To answer, they turned to the UK Biobank accelerometry sub-study, in which tens of thousands wore wrist accelerometers for a week while machine-learning classifiers separated genuine vigorous bursts from ordinary wrist noise. The researchers focused on the people the guidelines have written off: 25,241 adults reporting no leisure-time exercise and no more than one recreational walk per week, average age 61.8. Over 6.9 years of follow-up, 852 of them died.
The dose-response curve came out close to a straight line. Compared with participants who recorded no VILPA at all, those at the sample median of three one-to-two-minute bouts a day showed 38 to 40 percent lower all-cause and cancer mortality, and 48 to 49 percent lower cardiovascular mortality. The median total dose was 4.4 minutes a day, and four minutes of hurrying, scattered through the day, tracked with the kind of mortality difference researchers usually associate with a real training habit.
The team then ran the same analysis on 62,344 UK Biobank participants who did exercise, measuring vigorous exercise rather than incidental bursts, and the mortality reductions were comparable, which is the counterintuitive core of the December 2022 Nature Medicine paper, because it upends a decades-old rule of exercise physiology: bouts shorter than ten minutes do not count, a rule the guidelines stated explicitly before quietly dropping it in 2018, though the field never abandoned it in spirit. The VILPA data suggest the ten-minute threshold was never the biology, because the biology responds to intensity, and fast: 93 percent of recorded VILPA bouts lasted under a minute, the average bout about 45 seconds.
In a British Journal of Sports Medicine follow-up, the same group tracked major cardiovascular events, heart attacks, heart failure, and strokes in 22,368 non-exercisers over 7.9 years. Among women, 3.4 minutes of VILPA a day was associated with a 45 percent lower risk of major cardiovascular events and a 67 percent lower risk of heart failure, and the minimum effective dose was the most striking of all: 1.2 to 1.6 minutes a day, about ninety seconds, tracked with a 30 percent reduction in cardiovascular events. A separate 2022 European Heart Journal analysis found that 15 to 20 minutes a week of vigorous activity in short bouts was associated with 16 to 40 percent lower mortality.
Here is a calculation the papers never ran. The conventional prescription, 150 minutes a week of moderate activity, is associated in pooled analyses with roughly a 30 percent reduction in all-cause mortality versus inactivity, while the VILPA median dose, about 31 minutes a week, was associated with roughly 28 percent. Per weekly minute, the incidental bursts delivered about 0.9 percentage points of mortality reduction versus about 0.2 for structured moderate exercise: more than four times the return per minute invested. The comparison crosses cohorts and study designs, so treat it as illustrative arithmetic rather than a head-to-head trial. The direction, though, is hard to miss: intensity buys back time.
The Strongest Case Against
The strongest case against these results is that they measure sickness, not salvation, because nobody was randomized to sprint up stairs. The 11 percent who recorded zero VILPA were not a control group; they were, plausibly, the frailest people in the cohort, whose knees, lungs, or hearts had already ruled out hurrying. The authors adjusted for smoking, diet, sleep, and self-reported illness, and excluded early deaths in sensitivity analyses, but statistical adjustment cannot fully separate a body that cannot move fast from a death that movement might have prevented; reverse causation is the classic killer of exercise epidemiology, and it applies here at full force.
Two more wrinkles. First, the cardiovascular follow-up found the clear dose-response only in women, while in men the curves were flatter and often not statistically significant, with a significant sex-by-VILPA interaction. If the mechanism were pure biology, it should not care much about sex, which hints that some of what the accelerometers captured was behavior or confounding dressed as exercise. Second, wrist accelerometers and machine learning beat questionnaires, but classification is imperfect, and the UK Biobank is famously healthy, affluent, and overwhelmingly white. None of this sinks the finding, but it does mean the 40 percent figure is the observed association in one population, not a prescription you can bank.
What We Didn't Prove
This was an observational study: nobody proved that adding stair-sprints causes longer life, since a randomized trial of incidental daily activity is essentially impossible to run, so causation will have to be built from converging evidence.
The sample averaged 61.8 years old; whether younger or much older adults get the same bargain is untested.
VILPA will not build muscle, bone density, or balance; strength training owns those outcomes, and no amount of stair-hurrying replaces resistance work for aging muscle. This research lowers the bar for cardiovascular and mortality benefits; it does not retire the gym.
Absolute risk matters more than relative risk: about 3.4 percent of the cohort died during follow-up (852 of 25,241), so a 40 percent relative reduction is roughly 1.4 percentage points in absolute terms, meaningful at population scale and modest for any individual.
What You Can Do
Take the stairs at a pace that leaves you slightly breathless for sixty to ninety seconds at a time; that is the entire intervention.
Stack the bouts onto things you already do, parking far and walking fast, getting off transit one stop early and hurrying, carrying the groceries briskly, playing hard with the kids or the dog, and aim for three or four bursts a day, because ninety seconds is the minimum viable dose in the women's data, so even one honest stair climb beats zero.
Do not try to bank it: the dose-response was daily, not weekly, so a Saturday sprint does not obviously cover a sedentary week. And keep the weights: VILPA appears to buy longevity through the cardiovascular system, while muscle still has to be earned the old-fashioned way.
The Bottom Line
For decades, exercise advice treated the workout as a scheduled event and everything else as rounding error. The best-measured evidence says the rounding error was doing a large share of the work. Four minutes a day of moving vigorously through ordinary life tracked with mortality reductions that rival a dedicated exercise habit. The gym is not obsolete. It was never the whole story.